JAGX Tingkat bathi reged Jaguar Health Corp

Jaguar Health, Inc. (JAGX) develops plant-based treatments to combat diarrhea in HIV and oncology patients, targeting a massive global market. The gross margin variance illustrates sales profitability, while 74.30 shows the current value of the metric. The company's moat is based on patents and the complexity of sourcing raw materials from the jungle. R&D activity is focused on completing Phase 3 trials for crophlemer.
Rincian metrik keuangan lan pasar Jaguar Health Corp (JAGX)

Gross margin is calculated as the difference between total revenue and the direct cost of goods sold, determining the efficiency of production cost management. An increase in this ratio confirms the high added value of the product and the business model's resilience to costs. For Jaguar Health, Inc. (JAGX), stable sales of its specialized drug offset macroeconomic risks, which is reflected in a steady gross margin structure.